Cohere has acquired Reliant AI, a Montréal- and Berlin-based biopharma research startup, folding its automated literature-review engine into Cohere's North platform to launch "North for Pharma" — an agentic system aimed at drug-discovery and clinical-development teams. Announced May 19, the deal is Cohere's second acquisition in roughly a month, following its April move on German sovereign-AI firm Aleph Alpha. Terms were not disclosed; Reliant raised an $11.3M seed round in August 2024, bringing its total funding to $13.5M.
What Cohere is buying
Reliant's product is an "intelligent research workbench" that automates systematic literature reviews, competitive landscaping, and extraction of unstructured scientific and regulatory data — the evidence-gathering that R&D and regulatory-affairs teams otherwise do by hand across thousands of papers, filings, and trial records. Reliant brings roughly 30 employees split between Montréal and Berlin, plus pharma customers including GSK and Kyowa Kirin, who transfer to Cohere.
The founders carry research weight. CEO Karl Moritz Hermann becomes VP of AI Verticalizations in Berlin, and co-founder Marc Bellemare — a Canada CIFAR AI Chair at Mila — becomes VP of Modelling in Montréal. Co-founder Richard Schlegel rounds out the team.
Why it fits the sovereign-AI thesis
Cohere has staked its enterprise position on deployment models that keep weights and data inside the customer's perimeter — on-prem, VPC, or air-gapped — rather than behind a public API. That's a deliberate contrast with OpenAI and Anthropic's hosted-first posture, and it maps to what regulated buyers in pharma, operating under GxP, HIPAA, and EMA/FDA constraints, tend to require. "Healthcare represents one of the most consequential opportunities for AI and it demands secure, sovereign, and domain-specific systems," CEO Aidan Gomez said.
North for Pharma will target R&D, clinical development, and scientific analytics workflows. In practice, that means agents that can read a corpus of literature and regulatory filings, surface therapeutic precedents, and model market viability — under the data-residency and audit controls life-sciences compliance teams demand. Hermann framed the move as a chance "to scale our biopharma AI solutions globally while maintaining the security and sovereignty that life sciences organizations require."
What changes for builders and buyers
For enterprise teams evaluating vertical agents, the signal is consolidation: general-purpose model vendors are buying domain-specific tooling rather than expecting customers to assemble it. Pairing Reliant's pharma data plumbing with North's agent orchestration shortens the path from "we have a foundation model" to "we have a validated R&D workflow."
It also sharpens the sovereign-versus-hosted divide. Cohere is betting that the next wave of enterprise AI spend in regulated sectors flows to vendors who can prove data control, not just post benchmark scores. With Aleph Alpha covering sovereign deployments in Europe and now Reliant covering regulated life sciences, Cohere is assembling a verticalized, compliance-first stack — and giving CISOs and regulatory leads a concrete reason to shortlist it against the API incumbents.
